Brainomix 360 e-CTA vs Neosoma Platform

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Brainomix 360 e-CTA

by Brainomix Limited

Neosoma Platform

by Neosoma

AI Verdict

Brainomix 360 e-CTA and Neosoma Platform are adjacent competitors in the neuroimaging AI space, both offering clinical decision support and radiology AI. Brainomix 360 e-CTA focuses specifically on acute stroke, providing automated assessment of collaterals and large vessel occlusions on CT angiography scans. Neosoma Platform, on the other hand, specializes in neuro-oncology, offering automated tumor mapping, lesion tracking, and real-time insights for brain metastases and gliomas on MRI scans.

Choose Brainomix 360 e-CTA if…

Choose Brainomix 360 e-CTA if your primary need is rapid and automated assessment of acute stroke patients, specifically for detecting large vessel occlusions (LVOs) and evaluating collateral circulation on CT angiography scans. This tool is ideal for emergency medicine and stroke teams aiming to expedite treatment decisions like thrombectomy, as it provides quick, consistent analysis and can integrate with mobile alerts.

View Brainomix 360 e-CTA →

Choose Neosoma Platform if…

Choose Neosoma Platform if your focus is on comprehensive, longitudinal management of neuro-oncology patients with brain metastases or gliomas. This cloud-based AI tool excels at automated tumor mapping, lesion tracking over time, and providing real-time insights for clinical decisions, research, and clinical trials.

View Neosoma Platform →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Brainomix 360 e-CTA	Neosoma Platform
Pricing	Contact vendor	Volume-based
Deployment	Cloud service (EU and US) and on-site server within the hospital network.	Cloud
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Cleared AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Neosoma Platform

Neosoma Platform emphasizes an intuitive, web-based interface that allows users to be up and running in minutes, and it's designed for multidisciplinary teams with multiple logins without incremental seat licenses. Brainomix 360 e-CTA offers results via PACS, mobile app, email, or web UI, and a mobile app for quick access and care coordination. However, Neosoma's explicit mention of an 'intuitive, web-based interface' and 'up and running in just a few minutes' suggests a slightly stronger focus on immediate user-friendliness.

Clinical Value

Brainomix 360 e-CTA

Brainomix 360 e-CTA has extensive clinical validation with over 60 peer-reviewed studies demonstrating its accuracy and impact on stroke care, including a 100% increase in thrombectomy rates and reduced door-in-door-out times. While Neosoma Platform has FDA clearances and publications validating its tumor segmentation and tracking, the breadth and depth of published real-world impact for Brainomix in acute stroke management appear more substantial.

Pricing & Value

Neosoma Platform

Neosoma Platform offers transparent volume-based pricing, allowing multiple team members access without additional seat licenses, which provides clear value for multidisciplinary teams. Brainomix 360 e-CTA's pricing is 'contact vendor,' which offers less transparency upfront. While both aim to provide value through improved clinical outcomes, Neosoma's pricing model is more clearly articulated as beneficial for broader team adoption.

Enterprise Readiness

Neosoma Platform

Neosoma Platform is SOC2 Type II certified and HIPAA compliant, explicitly stating PACS integration and interoperability with various treatment planning systems. Brainomix 360 e-CTA implies HIPAA compliance and GDPR adherence, and offers cloud or on-site deployment, but Neosoma's explicit SOC2 certification and broad interoperability with treatment planning systems suggest a more robust enterprise-ready solution.

Innovation

Tie

Both tools demonstrate significant innovation in their respective fields. Brainomix 360 e-CTA offers automated collateral assessment and LVO detection for acute stroke, leveraging AI for rapid decision-making. Neosoma Platform provides automated tumor mapping, longitudinal lesion tracking, and real-time insights for neuro-oncology, with a modular regulatory architecture for rapid new indication clearances. Their innovative approaches are tailored to different clinical needs, making it difficult to declare one definitively more innovative than the other.

Support & Docs

Brainomix 360 e-CTA

Brainomix 360 e-CTA explicitly mentions user manuals, FAQs, and a contact us section on its website, indicating readily available support resources. While Neosoma's platform is designed for ease of use, specific details about comprehensive support documentation like user manuals or extensive FAQs are not as prominently featured in the provided information.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Brainomix 360 e-CTA	Neosoma Platform
Name	Brainomix 360 e-CTA	Neosoma Platform
Company	Brainomix Limited	Neosoma
Description	Brainomix 360 e-CTA is an AI-powered module within the Brainomix 360 Stroke platform that automates and standardizes the assessment of collaterals and detects large vessel occlusions on CT angiography scans for acute stroke patients.	The Neosoma Platform is a cloud-based, FDA-cleared AI tool for neuro-oncology, providing automated tumor mapping, lesion tracking, and real-time insights for brain metastases and gliomas.
Key Features	Automated collateral assessment on CTA scans, Computation of CTA Collateral Score (CTA-CS), Automatic Large Vessel Occlusion (LVO) detection, Indication of CTA acquisition phase for quality control, Multi-planar reconstructions (MPRs) with coronal, sagittal, and axial viewing, Integration within Brainomix 360 Stroke platform, DICOM results sent automatically to PACS or other radiology systems, Email result notifications.	PACS Integration, Automated DICOM study analysis, Longitudinal lesion tracking, Real-time insights for clinical decisions, MRI Protocol Tolerant (no changes needed), SOC2 Type II certified and HIPAA compliant, Interoperable with treatment planning systems (Eclipse, MIM, Gamma Plan, Stealth), Interactive 3D/2D visualizations and smart editing tools.
Specialties	Emergency Medicine, Neurology, Radiology	Neurology-AI, Oncology-AI

Videos

Demos, reviews, and walkthroughs featuring Brainomix 360 e-CTA and Neosoma Platform.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows for acute stroke and neuro-oncology, respectively?

Brainomix 360 e-CTA is designed to integrate into acute stroke workflows by automatically sending DICOM results to PACS or other radiology systems and providing email notifications. Neosoma Platform integrates with PACS for automated DICOM study analysis and is interoperable with various treatment planning systems like Eclipse, MIM, Gamma Plan, and Stealth, fitting into neuro-oncology workflows.

What is the depth of EHR integration for each tool, and how does this impact data flow and physician access to insights?

Brainomix 360 e-CTA primarily focuses on sending DICOM results to PACS, which can then be accessed within the EHR if PACS is integrated. Neosoma Platform offers PACS integration and data export capabilities, which can facilitate deeper integration with EHR systems for comprehensive patient data access and longitudinal tracking within the neuro-oncology context.

What are the key differences in accuracy and sensitivity for detecting abnormalities, specifically for collateral assessment in stroke and tumor mapping in neuro-oncology?

Brainomix 360 e-CTA provides automated collateral assessment on CTA scans, including computation of a CTA Collateral Score and automatic Large Vessel Occlusion (LVO) detection. Neosoma Platform offers automated tumor mapping and longitudinal lesion tracking for brain metastases and gliomas, providing real-time insights for clinical decisions in neuro-oncology.

Given their specialized focus, what is the expected learning curve for physicians in Emergency Medicine, Neurology, and Radiology using Brainomix 360 e-CTA versus neuro-oncology teams using Neosoma Platform?

Brainomix 360 e-CTA is designed for acute stroke, providing automated analysis and DICOM results, which suggests a relatively quick integration into existing radiology reading workflows. Neosoma Platform, with its interactive 3D/2D visualizations and smart editing tools, may require a slightly longer learning curve for neuro-oncology teams to fully leverage its advanced features for tumor mapping and tracking.

Beyond HIPAA, what additional security measures and audit-trail features do these platforms offer to ensure data integrity and accountability?

Brainomix 360 e-CTA operates as a cloud service and on-site server, adhering to GDPR, which implies robust data protection, and its DICOM results sent to PACS would be part of existing audit trails. Neosoma Platform is SOC2 Type II certified and HIPAA compliant, indicating strong security controls and likely comprehensive audit-trail features for all actions performed within the platform.

How do these tools support multi-site rollout, and what considerations should be made for consistent implementation and data management across different hospital locations?

Brainomix 360 e-CTA, with its cloud and on-site deployment options, can support multi-site rollouts by offering flexibility in infrastructure. Neosoma Platform, being cloud-based, is inherently scalable for multi-site deployment, allowing multiple team members to have logins and facilitating consistent data access and management across different locations.

Can you provide information on customer references or case studies demonstrating the time-to-value and clinical impact of these tools in real-world settings?

Brainomix 360 e-CTA emphasizes turning 'ordinary scans into extraordinary insights, enabling precision medicine for better treatment decisions' in acute stroke, suggesting a focus on rapid clinical impact. Neosoma Platform aims to serve 'the multidisciplinary neuro-oncology clinical team, researchers and clinical trials' with real-time insights, implying a focus on accelerating clinical decision-making and research. Specific customer references or case studies would need to be obtained directly from the vendors.

More Comparisons

eCARTv5 Clinical Deterioration Suite (eCART) vs Google Med-PaLM 2

ChatGPT vs Google Med-PaLM 2

When choosing between ChatGPT and Google Med-PaLM 2, physicians should consider their primary use case and desired level of medical…

Brainomix 360 e-CTA vs Google Med-PaLM 2

DeepXray vs Google Med-PaLM 2

More matchups featuring Brainomix 360 e-CTA or Neosoma Platform

Backers

Who funded each tool's parent company.

Brainomix 360 e-CTA

Modi Ventures